Product Specification
| Alternative Name: | OPG, TNFRSF 11B, Osteoclastogenesis inhibitory factor |
| |
| Source: | Produced in HEK 293 cells. The cysteine-rich region of human OPG (osteoprotegerin) (aa 22-202) is fused to the Fc portion of human IgG1. |
| |
| UniProt ID: | O00300 |
| |
| Concentration: | 1mg/ml after reconstitution. |
| |
| Formulation: | Lyophilized. Contains PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Bio Whittaker). |
| |
| Species reactivity: | Human, Mouse
|
| |
| Specificity: | Binds human and mouse RANKL and TRAIL. |
| |
| Applications: | ELISA
|
| |
| Application Notes: | ELISA: binds to osteoprotegerin receptor. |
| |
| Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Scientific Background: | Osteoprotegerin (OPG) is a secreted tumor necrosis factor receptor homologue that inhibits osteoclastogenesis and increases bone density in vivo. OPG contains 4 cysteine-rich repeats and 2 |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95: C. Assohou-Luty, et al.; J. Mol. Med.
84, 785 (2006),
Abstract;
Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis: P. Collin-Osdoby, et al.; J. Biol. Chem.
276, 20659 (2001),
Abstract;
Full Text
Related Products
